Aliases & Classifications for Mucositis

MalaCards integrated aliases for Mucositis:

Name: Mucositis 12 54 43 15 17
Inflammatory Disease of Mucous Membrane 71
Gastrointestinal Mucositis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0080178
MeSH 43 D052016
UMLS 71 C0333355 C0521585

Summaries for Mucositis

Disease Ontology : 12 A gastrointestinal system disease that is characterized by painful inflammation and ulceration of the mucous membranes lining the digestive tract.

MalaCards based summary : Mucositis, also known as inflammatory disease of mucous membrane, is related to kaposi sarcoma and melanoma, and has symptoms including signs and symptoms, digestive, oral manifestations and catarrh. An important gene associated with Mucositis is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Posaconazole and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and bone marrow, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 74 Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract,... more...

Related Diseases for Mucositis

Diseases related to Mucositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1716)
# Related Disease Score Top Affiliating Genes
1 kaposi sarcoma 32.2 VEGFA MTOR CSF2 CASP3
2 melanoma 32.0 VEGFA MTOR IL2 HGF EGF CSF2
3 gastric ulcer 31.8 VEGFA HGF EGF
4 diarrhea 31.7 IL2 HTR3A CSF3 ABCB1
5 squamous cell carcinoma, head and neck 31.5 XRCC1 VEGFA TYMS HGF EGF DPYD
6 atrophic gastritis 31.4 IL11 GHRL EGF
7 gingivitis 31.0 VEGFA IL2 CSF3
8 lymphocytic leukemia 31.0 IL2 CSF2 CASP3 ABCB1
9 short bowel syndrome 31.0 HGF GHRL FGF7 EGF
10 inflammatory bowel disease 31.0 VEGFA MTHFR IL2 IL11 HGF GHRL
11 exanthem 30.8 VEGFA MTOR IL2 CSF3 CSF2
12 neutropenia 30.7 TYMS IL11 DPYD CSF3 CSF2
13 severe combined immunodeficiency 30.7 VEGFA IL2 CSF3 CSF2 CASP3
14 fixed drug eruption 30.7 IL2 CASP3
15 osteonecrosis 30.6 VEGFA MTHFR ABCB1
16 acute leukemia 30.6 MTHFR CSF3 CSF2 ABCB1
17 stomatitis 30.6 TYMS MTOR IL2 FGF7 DPYD CSF3
18 interstitial cystitis 30.5 VEGFA IL2 EGF
19 gastroparesis 30.5 HTR3A GHRL ABCB1
20 pneumonia 30.5 VEGFA IL2 IL11 CSF3 CSF2
21 methotrexate toxicity 30.4 TYMS MTHFR ABCB1
22 gingival overgrowth 30.4 IL2 FGF7 ABCB1
23 hepatic veno-occlusive disease 30.3 VEGFA CSF3 ABCB1
24 smallpox 30.3 MTHFR IL2 CSF3 CSF2
25 plasmacytoma 30.3 VEGFA IL2 IL11
26 gastric adenocarcinoma 30.3 VEGFA TYMS MTOR IL11 EGF CASP3
27 colorectal adenocarcinoma 30.2 VEGFA TYMS EGF CASP3
28 chronic ulcer of skin 30.2 VEGFA FGF7 EGF
29 thrombocytopenia 30.2 IL2 IL11 CSF3 CSF2 CASP3 ABCB1
30 nasopharyngeal carcinoma 30.2 XRCC1 VEGFA MTOR EGF CASP3
31 gastrointestinal carcinoma 30.2 TYMS DPYD ABCB1
32 eye disease 30.2 VEGFA IL2 EGF CSF2 CASP3
33 ocular melanoma 30.1 VEGFA IL2 CASP3
34 colon adenoma 30.1 VEGFA EGF CASP3
35 osteogenic sarcoma 30.1 IL11 EGF CASP3 ABCB1
36 leukemia, acute lymphoblastic 30.1 XRCC1 TYMS MTHFR CSF3 CSF2 CASP3
37 gastrointestinal stromal tumor 30.1 VEGFA MTHFR CASP3 ABCB1
38 thymoma 30.1 VEGFA MTOR IL2 EGF CSF3
39 bladder cancer 30.1 XRCC1 VEGFA TYMS IL2 EGF CASP3
40 childhood leukemia 30.1 TYMS MTHFR CSF3 ABCB1
41 sarcoma 30.0 VEGFA MTOR CSF2 CASP3 ABCB1
42 meningitis 30.0 VEGFA IL2 CSF3 CSF2
43 colon adenocarcinoma 30.0 VEGFA TYMS EGF CASP3 ABCB1
44 dry eye syndrome 30.0 HGF FGF7 EGF
45 vascular disease 29.9 VEGFA MTHFR IL2 CSF3 CASP3
46 rheumatoid arthritis 29.9 VEGFA TGFB3 MTHFR IL2 IL11 CSF2
47 kidney cancer 29.9 VEGFA MTOR IL2 EGF CSF2
48 mantle cell lymphoma 29.9 VEGFA MTOR CSF3 CASP3
49 childhood acute lymphocytic leukemia 29.9 VEGFA MTHFR ABCB1
50 peripheral nervous system disease 29.9 VEGFA IL2 CSF3 CASP3

Graphical network of the top 20 diseases related to Mucositis:



Diseases related to Mucositis

Symptoms & Phenotypes for Mucositis

UMLS symptoms related to Mucositis:


signs and symptoms, digestive, oral manifestations, catarrh

MGI Mouse Phenotypes related to Mucositis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.32 ABCB1 CASP3 CSF2 DPYD FGF7 GHRL
2 growth/size/body region MP:0005378 10.3 ABCB1 CASP3 CSF2 EGF FGF7 HGF
3 endocrine/exocrine gland MP:0005379 10.22 ABCB1 CASP3 CSF2 EGF GHRL HTR3A
4 homeostasis/metabolism MP:0005376 10.22 ABCB1 CASP3 CSF2 FGF7 GHRL HTR3A
5 hematopoietic system MP:0005397 10.21 ABCB1 CASP3 CSF2 CSF3 FGF7 HGF
6 immune system MP:0005387 10.15 ABCB1 CASP3 CSF2 CSF3 EGF FGF7
7 digestive/alimentary MP:0005381 10.1 ABCB1 CASP3 DPYD EGF GHRL IL2
8 integument MP:0010771 10.02 CASP3 CSF2 CSF3 EGF FGF20 FGF7
9 nervous system MP:0003631 10 ABCB1 CASP3 CSF2 FGF20 FGF7 HTR3A
10 no phenotypic analysis MP:0003012 9.7 ABCB1 CASP3 HGF IL2 MTHFR MTOR
11 renal/urinary system MP:0005367 9.56 CASP3 CSF2 CSF3 FGF7 HTR3A MTOR
12 reproductive system MP:0005389 9.4 ABCB1 CASP3 CSF2 DPYD EGF FGF7

Drugs & Therapeutics for Mucositis

Drugs for Mucositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 468)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
2
Ethanol Approved Phase 4 64-17-5 702
3
Metronidazole Approved Phase 4 443-48-1 4173
4
Hexetidine Approved, Investigational Phase 4 141-94-6
5
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
6
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
7
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
8
Gemcitabine Approved Phase 4 95058-81-4 60750
9
Ifosfamide Approved Phase 4 3778-73-2 3690
10
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
11
Methylene blue Approved, Investigational Phase 4 61-73-4
12
Histamine Approved, Investigational Phase 4 51-45-6 774
13
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Promethazine Approved, Investigational Phase 4 60-87-7 4927
16
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
17
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
18
Povidone Approved Phase 4 9003-39-8
19
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
20
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
21
Simethicone Approved Phase 4 8050-81-5
22
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
23
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
24 Mitomycins Phase 4
25 Anti-Infective Agents, Local Phase 4
26 Gastrointestinal Agents Phase 4
27 Chlorhexidine gluconate Phase 4
28 Disinfectants Phase 4
29
Erythritol Phase 4 149-32-6, 2418-52-2 169019
30 Cola Phase 4
31
Hydroxyitraconazole Phase 4
32 Cathartics Phase 4
33 Laxatives Phase 4
34 Picosulfate sodium Phase 4
35
protease inhibitors Phase 4
36 HIV Protease Inhibitors Phase 4
37
Isophosphamide mustard Phase 4 0
38
asparaginase Phase 4
39 Protective Agents Phase 4
40 Central Nervous System Depressants Phase 4
41 Neurotransmitter Agents Phase 4
42 Cytochrome P-450 Enzyme Inhibitors Phase 4
43 Antiparasitic Agents Phase 4
44 Hormone Antagonists Phase 4
45 Antiprotozoal Agents Phase 4
46 Steroid Synthesis Inhibitors Phase 4
47 Hormones Phase 4
48 Antiemetics Phase 4
49 Hypnotics and Sedatives Phase 4
50 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 551)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
2 Clinical and Microbiological Evaluation of the Effect of Probiotic Lactobacillus Reuteri Prodentis in the Treatment of Mucositis and Periimplantitis Unknown status NCT03047291 Phase 4 Probiotic
3 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
4 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
5 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
6 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
7 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
8 Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer Completed NCT00333099 Phase 4
9 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
10 The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Peri-implant Mucositis and Peri-implantitis. Completed NCT02023853 Phase 4 metronidazole gel
11 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
12 A Pilot Randomised Comparison of Bicarbonate Based Mouth Care Versus Biotene Based Mouth Care During Radiotherapy Completed NCT00138827 Phase 4 Biotene (mouth care)
13 Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash;Placebo
14 Impact of Oral Hygiene Gels on Peri-implant Mucositis Completed NCT03243591 Phase 4
15 Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
16 Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
17 A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
18 Effect of Eszopiclone (Lunesta) on Sleep Disturbance and Pain in Cancer Completed NCT00365261 Phase 4 Eszopiclone;Placebo
19 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
20 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
21 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
22 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin injection;Compound kushen injection
23 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
24 A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
25 Clinical and Microbiologic Outcomes of Adjunctive Antimicrobial Photodynamic Therapy in the Non-surgical Treatment of Peri-implant Disease Not yet recruiting NCT04187053 Phase 4 Saline;Methylene Blue
26 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
27 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
28 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
29 Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial Unknown status NCT02313792 Phase 3 Palifermin
30 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
31 Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults Unknown status NCT02173756 Phase 3 morphine gel;placebo gel
32 Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1" Unknown status NCT01007617 Phase 2, Phase 3
33 The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial Unknown status NCT02282839 Phase 3
34 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
35 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
36 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
37 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Unknown status NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
38 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
39 the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial Unknown status NCT00603759 Phase 3 celecoxib;placebo
40 Regenerative Treatment of Peri-Implantitis: Double Blind Randomized Controlled Clinical Trial Unknown status NCT02575274 Phase 2, Phase 3
41 Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation. Unknown status NCT01955772 Phase 3 Enteral nutrition alanyl-glutamin, Dipeptiven
42 Efficacy and Cost Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Locally Advanced Head and Neck Cancer to Prevent Aspiration Pneumonia. A Randomized Phase II-III Study Unknown status NCT01598402 Phase 2, Phase 3 amoxicillin/clavulanic acid suspension
43 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
44 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
45 To Access the Effects of Mucositis in Adults With Dental Implants Completed NCT01072201 Phase 3 Triclosan and Fluoride;Fluoride
46 Effect of Low-level Laser Therapy on Inflammatory Mediators Release During Chemotherapy-induced Oral Mucositis: a Randomized Preliminary Study Completed NCT02050373 Phase 3
47 Serial Controlled N-of-1 Trials of Topical Vitamin E as Prophylaxis for Chemotherapy-induced Oral Mucositis in Pediatric Patients Completed NCT00311116 Phase 2, Phase 3 Vitamin E
48 Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan Completed NCT01837446 Phase 2, Phase 3 2% morphine solution;Magnesium aluminum hydroxide;2% viscous lidocaine;Diphenhydramine
49 Prevention High Dose Chemotherapy Induced Mucositis by Using Zinc Sulfate Completed NCT01015183 Phase 2, Phase 3 Zinc Sulfate;Placebo
50 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer Completed NCT00615420 Phase 3

Search NIH Clinical Center for Mucositis

Cochrane evidence based reviews: mucositis

Genetic Tests for Mucositis

Anatomical Context for Mucositis

MalaCards organs/tissues related to Mucositis:

40
Breast, Bone, Bone Marrow, Lung, Myeloid, T Cells, Skin

Publications for Mucositis

Articles related to Mucositis:

(show top 50) (show all 9380)
# Title Authors PMID Year
1
The use of GLP-2 and related growth factors in intestinal diseases. 54 61
20336592 2010
2
Keratinocyte growth factor. 54 61
19456212 2009
3
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. 54 61
18829546 2008
4
Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. 54 61
18197435 2008
5
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. 54 61
18560408 2008
6
Cytokines following SCT: indications and controversies. 54 61
18545239 2008
7
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. 54 61
18299612 2008
8
The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature. 54 61
18632516 2007
9
DPYD*2A mutation: the most common mutation associated with DPD deficiency. 54 61
17165084 2007
10
Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. 54 61
17728847 2007
11
Interventions for treating oral mucositis for patients with cancer receiving treatment. 54 61
17443514 2007
12
Head and neck radiation and mucositis. 54 61
18660721 2007
13
Cancer treatment-induced oral mucositis. 54 61
17465250 2007
14
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. 54 61
17293228 2007
15
Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. 54 61
17059384 2006
16
A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. 54 61
16904525 2006
17
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. 54 61
16912178 2006
18
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. 54 61
16965690 2006
19
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. 54 61
16803675 2006
20
Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy. 54 61
16634706 2006
21
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. 54 61
16414253 2006
22
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. 54 61
16537186 2006
23
R-Spondin proteins: a novel link to beta-catenin activation. 54 61
16357527 2006
24
The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments. 54 61
16322806 2005
25
Mucosal protection by cytokines. 54 61
16232381 2005
26
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. 54 61
15683818 2005
27
Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. 54 61
16110136 2005
28
Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. 54 61
15623608 2004
29
Interventions for treating oral mucositis for patients with cancer receiving treatment. 54 61
15106165 2004
30
Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. 54 61
12649101 2003
31
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. 54 61
12697866 2003
32
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. 54 61
12759532 2003
33
Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. 54 61
12243825 2002
34
The effects of keratinocyte growth factor in preclinical models of mucositis. 54 61
12139710 2002
35
Are Central Eastern European countries involved in clinical trials of supportive care? 54 61
12029429 2002
36
A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. 54 61
11919725 2002
37
Biological actions and therapeutic potential of the glucagon-like peptides. 54 61
11832466 2002
38
Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. 54 61
11597377 2001
39
Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. 54 61
11545238 2001
40
Genomics and drug discovery. 54 61
11511852 2001
41
Comment on: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 54 61
11503611 2001
42
Repifermin. Human Genome Sciences/GlaxoSmithKline. 54 61
15995938 2001
43
Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. 54 61
11313683 2001
44
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. 54 61
11212269 2001
45
Prevention and management of mucositis in patients with cancer. 54 61
11053801 2000
46
Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. 54 61
10899677 2000
47
Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 54 61
10701730 2000
48
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. 54 61
10578158 1999
49
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. 54 61
10473079 1999
50
Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. 54 61
10389920 1999

Variations for Mucositis

Expression for Mucositis

Search GEO for disease gene expression data for Mucositis.

Pathways for Mucositis

Pathways related to Mucositis according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 VEGFA MTOR IL2 IL11 HGF FGF7
2
Show member pathways
13.74 VEGFA TGFB3 MTOR IL2 IL11 HGF
3
Show member pathways
13.52 VEGFA TGFB3 MTOR IL2 IL11 HGF
4
Show member pathways
13.31 TGFB3 IL2 HTR3A HGF FGF7 FGF20
5
Show member pathways
13.29 VEGFA IL2 IL11 HGF FGF7 FGF20
6
Show member pathways
13.26 TGFB3 MTOR IL2 IL11 HGF FGF7
7
Show member pathways
13.24 VEGFA TGFB3 IL2 HGF FGF7 FGF20
8
Show member pathways
13.2 TGFB3 IL2 IL11 HGF FGF7 FGF20
9
Show member pathways
13.04 TGFB3 MTOR IL2 HGF FGF7 FGF20
10
Show member pathways
13.02 TGFB3 MTOR IL2 HGF FGF7 FGF20
11
Show member pathways
12.85 VEGFA TGFB3 MTOR EGF CSF2 CASP3
12
Show member pathways
12.75 VEGFA MTOR IL2 HGF FGF7 FGF20
13 12.74 VEGFA TGFB3 HGF FGF7 FGF20 EGF
14
Show member pathways
12.72 VEGFA HGF FGF7 FGF20 EGF
15
Show member pathways
12.72 TGFB3 MTOR HGF FGF7 FGF20 EGF
16
Show member pathways
12.71 MTOR HGF FGF7 FGF20 EGF
17
Show member pathways
12.66 TGFB3 IL2 HGF FGF7 FGF20 EGF
18
Show member pathways
12.65 MTOR HGF FGF7 FGF20 EGF
19
Show member pathways
12.6 VEGFA TGFB3 MTOR HGF EGF
20
Show member pathways
12.38 VEGFA FGF7 FGF20 EGF CASP3
21
Show member pathways
12.38 TGFB3 MTOR IL2 HGF FGF7 FGF20
22 12.28 VEGFA MTOR HGF CASP3
23
Show member pathways
12.25 TGFB3 IL2 HGF FGF7 FGF20
24
Show member pathways
12.25 MTOR IL2 IL11 EGF CSF3 CSF2
25 12.17 VEGFA TGFB3 EGF CASP3
26 12.07 VEGFA IL11 HGF FGF7 EGF
27 12 VEGFA TGFB3 MTOR IL2 HGF FGF7
28 11.98 IL2 IL11 CSF3 CSF2
29 11.85 VEGFA TGFB3 IL11 CSF2
30
Show member pathways
11.74 IL2 CSF2 CASP3
31
Show member pathways
11.74 TYMS MTHFR DPYD
32 11.73 TGFB3 IL2 HGF FGF7 FGF20 EGF
33 11.71 TGFB3 IL2 CSF2
34 11.67 MTOR IL2 EGF
35
Show member pathways
11.64 VEGFA IL2 CSF2
36 11.53 TGFB3 HGF CSF3
37 11.52 HGF FGF7 EGF CSF3 CSF2
38 11.45 VEGFA FGF7 EGF
39
Show member pathways
11.43 VEGFA HGF EGF
40 11.26 TGFB3 MTOR HGF
41 11.23 VEGFA TGFB3 IL11 HGF EGF
42 11.22 IL2 IL11 CSF3 CSF2
43 10.84 EGF CASP3
44 10.51 TGFB3 IL2 IL11 HGF FGF7 FGF20

GO Terms for Mucositis

Cellular components related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 VEGFA TGFB3 IL2 IL11 HGF GHRL
2 extracellular region GO:0005576 9.4 VEGFA TGFB3 RSPO1 IL2 IL11 HGF
3 platelet alpha granule lumen GO:0031093 9.26 VEGFA TGFB3 HGF EGF

Biological processes related to Mucositis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.23 VEGFA TGFB3 IL11 HTR3A GHRL FGF7
2 negative regulation of apoptotic process GO:0043066 10.03 VEGFA IL2 HGF GHRL CASP3
3 response to drug GO:0042493 9.92 XRCC1 TYMS MTHFR CASP3 ABCB1
4 wound healing GO:0042060 9.81 TGFB3 MTOR CASP3
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 VEGFA IL11 CSF3
6 positive regulation of protein phosphorylation GO:0001934 9.8 VEGFA RSPO1 MTOR IL2 HGF
7 MAPK cascade GO:0000165 9.8 IL2 HGF FGF7 FGF20 EGF CSF2
8 platelet degranulation GO:0002576 9.78 VEGFA TGFB3 HGF EGF
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 VEGFA IL2 CSF2
10 response to hypoxia GO:0001666 9.77 XRCC1 VEGFA TGFB3 MTHFR CASP3
11 activation of MAPK activity GO:0000187 9.76 TGFB3 HGF GHRL EGF
12 positive chemotaxis GO:0050918 9.74 VEGFA HGF FGF7
13 positive regulation of cell division GO:0051781 9.73 VEGFA TGFB3 FGF7
14 response to ethanol GO:0045471 9.73 TYMS IL2 HTR3A CSF3
15 positive regulation of protein kinase B signaling GO:0051897 9.73 MTOR HGF FGF7 FGF20 EGF CSF3
16 cytokine-mediated signaling pathway GO:0019221 9.7 VEGFA IL2 IL11 HGF CSF3 CSF2
17 response to amino acid GO:0043200 9.69 MTOR MTHFR CASP3
18 positive regulation of keratinocyte migration GO:0051549 9.62 MTOR FGF7
19 tetrahydrofolate interconversion GO:0035999 9.61 TYMS MTHFR
20 tetrahydrofolate metabolic process GO:0046653 9.61 TYMS MTHFR
21 positive regulation of cell proliferation GO:0008284 9.61 VEGFA TGFB3 IL2 IL11 FGF7 FGF20
22 response to folic acid GO:0051593 9.59 TYMS MTHFR
23 voluntary musculoskeletal movement GO:0050882 9.58 XRCC1 MTOR
24 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.55 HGF FGF7
25 regulation of response to food GO:0032095 9.54 MTOR GHRL
26 positive regulation of eating behavior GO:1904000 9.49 MTOR GHRL
27 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.17 VEGFA MTOR IL11 HGF FGF7 EGF

Molecular functions related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 VEGFA TGFB3 IL2 IL11 CSF3 CSF2
2 chemoattractant activity GO:0042056 9.33 VEGFA HGF FGF7
3 growth factor activity GO:0008083 9.32 VEGFA TGFB3 IL2 IL11 HGF FGF7

Sources for Mucositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....